- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05002634
Safety of Undenatured Collagen Type II (UCII) Supplement in Healthy Volunteer
August 10, 2021 updated by: Pornanong Aramwit, Pharm.D., Ph.D, Chulalongkorn University
This study will be evaluated safety of undenatured collagen type II (UCII) supplement in 60 healthy volunteer.
Liver function test, renal function test, and adverse event will be assessed.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study will be evaluated safety of undenatured collagen type II (UCII) supplement in 60 healthy volunteer.
The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
Liver function test, renal function test, and adverse event will be assessed before and after taking for 1 and 2 months.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 20-60 years
- No taking collagen supplement more than 2 weeks
- No collagen and protein allergy
- No liver and renal disease
- Have a willingness to participate in the study
Exclusion Criteria:
- Uncontrolled disease
- Have complication symptom during study
- Pregnancy or lactation
- Cannot follow the protocol
- During participated in other studies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: undenatured collagen type II (UCII) supplement
The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
|
The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aspartate aminotransferase value
Time Frame: 2 months
|
Aspartate aminotransferase value (U/L) in blood sample
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alkaline phosphatase value
Time Frame: 2 months
|
Alkaline phosphatase value (U/L) in blood sample
|
2 months
|
Alanine transaminase value
Time Frame: 2 months
|
Alanine transaminase value(U/L) in blood sample
|
2 months
|
Blood urea nitrogen value
Time Frame: 2 months
|
Blood urea nitrogen value (mg/dl) in blood sample
|
2 months
|
Creatinine value
Time Frame: 2 months
|
Creatinine value (mg/dl) in blood sample
|
2 months
|
Adverse event
Time Frame: 2 months
|
using questionnaire (Yes or No)
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 5, 2021
Primary Completion (Anticipated)
June 30, 2022
Study Completion (Anticipated)
July 31, 2022
Study Registration Dates
First Submitted
August 3, 2021
First Submitted That Met QC Criteria
August 10, 2021
First Posted (Actual)
August 12, 2021
Study Record Updates
Last Update Posted (Actual)
August 12, 2021
Last Update Submitted That Met QC Criteria
August 10, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- EC2104220
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Health, Subjective
-
Istanbul University - Cerrahpasa (IUC)Not yet recruitingHealth, Subjective
-
Bahçeşehir UniversityNot yet recruiting
-
BMI KoreaCompletedHealth, SubjectiveKorea, Republic of
-
Alteogen, Inc.CompletedHealth, SubjectiveKorea, Republic of
-
Tel Aviv UniversityCompletedHealth, SubjectiveIsrael
-
Hanmi Pharmaceutical Company LimitedCompletedHealth, SubjectiveKorea, Republic of
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealth, Subjective
-
Prince Sattam Bin Abdulaziz UniversityCompletedHealth, SubjectiveSaudi Arabia
-
Çankırı Karatekin UniversityCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineCompleted
Clinical Trials on undenatured collagen type II (UCII) supplement
-
National Eye Institute (NEI)CompletedUveitis | Arthritis, Juvenile RheumatoidUnited States
-
BioibericaRecruiting
-
University of TennesseeNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Vedic Lifesciences Pvt. Ltd.Recruiting
-
Quadram Institute BioscienceUniversity of Sheffield; Food Standards Agency, United KingdomCompleted
-
TakedaCompletedDiabetes MellitusUnited States, Argentina, Mexico, Peru, Chile
-
NPO PetrovaxCompletedOsteoarthritis | Knee Osteoarthritis | Osteoarthritis, Knee | Knee Arthritis | Knee Discomfort | Knee Pain Chronic | Knee Pain SwellingRussian Federation
-
Bristol-Myers SquibbCompletedAdvanced CancerUnited States, Canada
-
Peking Union Medical College HospitalUnknown
-
NSABP Foundation IncHoffmann-La Roche; Genentech, Inc.; International Drug Development InstituteCompleted